Cardiovascular

LifeTech Scientific Secures Strategic Investment from GL Capital and Zylox-Tonbridge to Build Pan-Vascular and Structural Heart Platform

LifeTech Scientific has brought in a joint strategic investment from GL Capital and Zylox-Tonbridge through a vehicle that will subscribe to newly issued shares for approximately HK$1.482 billion and hold about 16.7% of LifeTech’s enlarged issued share capital, with the parties intending to pursue a future merger to build a leading pan-vascular and structural heart intervention platform in China.

Read More